Get the Stockscreener App
14.40
3.19%
-0.51
Zymeworks Inc. stock is traded at $14.40, with a volume of 129.54K.
It is down -3.19% in the last 24 hours and up +0.87% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$14.91
Open:
$14.79
24h Volume:
129.54K
Relative Volume:
0.28
Market Cap:
$1.03B
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
-9.5364
EPS:
-1.51
Net Cash Flow:
$-96.01M
1W Performance:
-1.13%
1M Performance:
+0.87%
6M Performance:
+46.85%
1Y Performance:
+27.41%
1-Day Range:
$14.19
$14.96
1-Week Range:
$14.15
$15.14
52-Week Range:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.41 | 1.03B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.55 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.08 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.85 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Recent Insider Activity Could Benefit Zymeworks BC Inc (ZYME) - Knox Daily
You might want to take a look at Zymeworks BC Inc (ZYME) now - SETE News
SG Americas Securities LLC Has $392,000 Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks to Engage Investors at Key Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Cancer Drug Developer Zymeworks Takes Center Stage at Oppenheimer, Citi, and B. Riley Events - StockTitan
Zymeworks (NASDAQ:ZYME) shareholder returns have been respectable, earning 79% in 3 years - Simply Wall St
The past five years for Zymeworks (NASDAQ:ZYME) investors has not been profitable - Yahoo Finance
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 19,748 Shares - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Analysts Set Zymeworks Inc. (NYSE:ZYME) PT at $19.17 - MarketBeat
EcoR1 Capital, LLC Expands Stake in Zymeworks Inc with Strategic Acquisition - GuruFocus.com
Assenagon Asset Management S.A. Raises Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Assenagon Asset Management S.A. Boosts Stake in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Engineered Multispecific Antibodies Innovation Research Report 2024: Patent Trends Show a Noticeable Surge in 2023 with Regeneron, Roche, and Amgen Emerging as the Top Patent Filers - GlobeNewswire Inc.
Zymeworks (NYSE:ZYME) Shares Gap Up Following Insider Buying Activity - Defense World
Opinion: Four trends to watch in B.C.'s tech sector - Business in Vancouver
Zymeworks (NYSE:ZYME) Shares Gap Up on Insider Buying Activity - MarketBeat
EcoR1 Capital, LLC Increases Stake in Zymeworks Inc - GuruFocus.com
ZYME (Zymeworks) Total Stockholders Equity : $366.98 Mil (As of Sep. 2024) - GuruFocus.com
Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 74,125 Shares of Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock By Investing.com - Investing.com Nigeria
Ecor1 Capital, Llc Buys 39,029 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock - Investing.com
Ecor1 capital increases stake in Zymeworks with $2.97 million purchase By Investing.com - Investing.com South Africa
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 204,098 Shares of Stock - MarketBeat
Ecor1 Capital, Llc Purchases 21,021 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital increases stake in Zymeworks with $2.97 million purchase - Investing.com
Zymeworks in Focus for Insider Activity: Catalysts Ahead - Benzinga
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 - The Manila Times
Zymeworks Sets Strategic Milestones for 2025-2026 with Focus on Novel Therapeutics - TipRanks
Zymeworks says it has enough cash to operate through H2 2027 - Seeking Alpha
Zymeworks Unveils 2025 Pipeline Strategy: Multiple INDs Planned, $324M Cash Position Supports Growth - StockTitan
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 41.36%: Here's is How to Trade - Yahoo Finance
Zymeworks CEO Kenneth Galbraith sells $855,016 in stock By Investing.com - Investing.com Australia
Zymeworks chief scientific officer sells shares worth $316,390 By Investing.com - Investing.com Australia
Zymeworks Inc. (NYSE:ZYME) CEO Sells $854,781.72 in Stock - MarketBeat
Insider Selling: Zymeworks Inc. (NYSE:ZYME) EVP Sells 11,110 Shares of Stock - MarketBeat
Paul Andrew Moore Sells 21,200 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Zymeworks chief scientific officer sells shares worth $316,390 - Investing.com
Zymeworks CEO Kenneth Galbraith sells $855,016 in stock - Investing.com
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zymeworks Inc. Stock (ZYME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
Jan 17 '25 |
Buy |
13.87 |
19,748 |
273,998 |
15,720,161 |
| EcoR1 Capital, LLC | Director |
Jan 13 '25 |
Buy |
13.39 |
74,125 |
992,875 |
15,485,203 |
| EcoR1 Capital, LLC | Director |
Jan 14 '25 |
Buy |
13.56 |
54,500 |
739,265 |
15,539,703 |
| EcoR1 Capital, LLC | Director |
Jan 15 '25 |
Buy |
14.01 |
39,029 |
546,671 |
15,578,732 |
| EcoR1 Capital, LLC | Director |
Jan 10 '25 |
Buy |
13.13 |
204,098 |
2,678,990 |
15,411,078 |
| EcoR1 Capital, LLC | Director |
Jan 08 '25 |
Buy |
14.07 |
21,021 |
295,829 |
15,206,980 |
| Moore Paul Andrew | Chief Scientific Officer |
Jan 06 '25 |
Option Exercise |
0.00 |
37,166 |
0 |
34,741 |
| Moore Paul Andrew | Chief Scientific Officer |
Jan 06 '25 |
Sale |
14.92 |
21,200 |
316,391 |
14,741 |
| Galbraith Kenneth | Chair & CEO |
Jan 06 '25 |
Option Exercise |
0.00 |
114,332 |
0 |
114,209 |
| Galbraith Kenneth | Chair & CEO |
Jan 06 '25 |
Sale |
14.92 |
57,291 |
855,017 |
47,543 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):